Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis
Wei Zhu(Ministry of Education of the People's Republic of China), Zipeng Xu(Wuxi People's Hospital), Qifeng Shi(Shanxi Agricultural University), Lu Chen(National Clinical Research), Zhang Ye(Inner Mongolia Medical University), Chaobo Chen(Wuxi People's Hospital), Lingyun Yang(Sichuan University)
Cited by 2
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168